Laura Moran | White & Case LLP International Law Firm, Global Law Practice
 Laura Moran
 Laura Moran

Laura Moran

Associate, New York

T +1 212 819 8948



Laura Moran is an associate in the New York office and a member of the firm's Global Competition Group. Her practice focuses on complex patent disputes, including infringement litigation in the pharmaceutical industry arising under the Hatch-Waxman Act.

Laura also supports the firm's transactional practice in matters related to intellectual property rights and the evaluation of intellectual property portfolios.  She has additionally represented clients in arbitration involving patent licensing rights.

Laura is active in the firm's pro bono work and has represented indigent victims of domestic violence in family and matrimonial law cases as the White & Case extern to Her Justice.

Bars and Courts

  • New York State Bar
  • US District Court for the Southern District of New York
  • US Court of Appeals for the Federal Circuit


  • JD, University of Notre Dame Law School
  • BS, Loyola University, Maryland


  • English


Representation through trial of UCB and Pfizer in Hatch-Waxman litigation against 12 generic defendants for infringement of five patents covering the incontinence drug Toviaz® in the U.S. District Court for the District of Delaware.

Representation of UCB, at trial in the U.S. District Court for the Southern District of Florida and on appeal to the Federal Circuit, defending against patent infringement claims brought by Apotex against UCB's Univasc® and Uniretic® products. The District Court found the case "exceptional" under 35 U.S.C. § 285 and granted a full award of attorney fees and costs in addition to expert witness fees and prejudgment interest.

Representation of Swiss pharmaceutical company, IBSA Institut Biochimique SA in patent litigation concerning its medicated patch Flector®.

Representation of Pfizer in Hatch-Waxman litigation in the U.S District Court for the District of Delaware regarding patents covering the antidepressant Pristiq®.

Representation of Novo Nordisk in Hatch-Waxman litigation concerning the drug Vagifem® against three generic challengers.